OPEN ACCESS Freely available online

Lupus: Open Access

Short Communication

Understanding Low White Blood Cell Counts and Leukopenia

Maya Lin*

Department of Immunology, University of Kyoto, Kyoto, Japan

DESCRIPTION

White Blood Cells (WBCs) are a crucial part of the immune system, responsible for protecting the body against infections caused by bacteria, viruses, fungi, and other harmful organisms. When the number of white blood cells in the blood drops below the normal range, the condition is known as leukopenia. Although leukopenia itself is not a disease, it is an important medical finding that can signal an underlying health problem or an effect of medication or treatment. Understanding its causes, symptoms, risks, and management is essential for proper diagnosis and care.

A normal white blood cell count typically ranges from about 4,000 to 11,000 cells per microliter of blood, although this range may vary slightly depending on the laboratory. Leukopenia is generally diagnosed when the count falls below 4,000 cells per microliter. In some cases, a specific type of white blood cell, such as neutrophils, may be reduced more significantly. This condition is called neutropenia and is particularly important because neutrophils are the body's first line of defense against bacterial infections.

Leukopenia can develop due to a wide variety of causes. One of the most common causes is bone marrow suppression. The bone marrow is the soft, spongy tissue inside bones where blood cells are produced. When bone marrow function is impaired, production of white blood cells decreases. This can occur due to viral infections, certain cancers such as leukemia, or exposure to toxic substances like radiation or chemotherapy drugs.

Certain medications are also known to reduce white blood cell counts. Drugs used in chemotherapy are among the most well-known causes because they target rapidly dividing cells, including cancer cells and healthy bone marrow cells. However, other medications such as some antibiotics, anticonvulsants, and immunosuppressive drugs can also contribute to leukopenia in some individuals. In many cases, adjusting or discontinuing the medication under medical supervision can help restore normal counts.

Autoimmune diseases are another important cause. In conditions such as Systemic Lupus Erythematosus, the immune system may mistakenly attack white blood cells or the bone marrow that produces them. This leads to reduced levels of circulating white blood cells and increases the risk of infection. Because autoimmune conditions can fluctuate over time, leukopenia may also vary in severity depending on disease activity.

Nutritional deficiencies can also contribute to low white blood cell counts. Deficiencies in essential nutrients such as vitamin B12, folate, copper, and protein can impair bone marrow function and reduce blood cell production. These deficiencies are more common in individuals with poor dietary intake, malabsorption disorders, or chronic illnesses affecting nutrient absorption.

Infections, particularly viral infections, can temporarily lower white blood cell counts. Viruses such as influenza, hepatitis, and Epstein-Barr virus can suppress bone marrow activity or cause white blood cells to be used up faster than they are produced. In many cases, leukopenia caused by infection is temporary and resolves once the infection is cleared.

Leukopenia itself does not always cause noticeable symptoms. Instead, symptoms are usually related to the underlying cause or the consequences of a weakened immune system. The most important clinical concern is an increased susceptibility to infections. Individuals with low white blood cell counts may experience frequent infections, fever, chills, sore throat, mouth ulcers, or slow healing of wounds. Severe leukopenia can lead to serious or life-threatening infections if not properly managed.

Diagnosis of leukopenia is typically made through a Complete Blood Count (CBC) test, which measures different components of blood, including white blood cells. If leukopenia is detected, further tests may be needed to determine the cause. These may include bone marrow biopsy, vitamin level assessments, viral testing, or autoimmune screening depending on the clinical context. Identifying the underlying cause is essential for guiding treatment.

Treatment of leukopenia depends entirely on its cause and severity. If a medication is responsible, doctors may adjust the dosage or switch to an alternative drug. In cases of nutritional deficiency, supplementation with vitamins or minerals can help restore normal white blood cell production. If an infection is

Correspondence to: Maya Lin, Department of Immunology, University of Kyoto, Kyoto, Japan, Email: mlin@celestial-inst.jp

Received: 27-Aug-2025, Manuscript No.LOA-25-42202;**Editor assigned:** 29-Aug-2025, PreQC No. LOA-25-42202 (PQ); **Reviewed:** 12-Sep-2025, QC No. LOA-25-42202; **Revised:** 19-Sep-2025, Manuscript No. LOA-25-42202 (R); **Published:** 26-Sep-2025, DOI: 10.35248/2684-1630.25.10.357

Citation: Lin M (2025). Understanding Low White Blood Cell Counts and Leukopenia. Lupus: Open Access. 10:357.

Copyright: © 2025 Lin M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

present, treating the infection often leads to recovery of white blood cell counts.

In more severe cases, especially when neutrophil counts are very low, doctors may prescribe medications that stimulate white blood cell production, such as Granulocyte Colony-Stimulating Factors (G-CSF). These treatments help the bone marrow produce more white blood cells and reduce the risk of serious infections. Patients with severe leukopenia may also require protective measures such as infection prevention strategies and close monitoring.

Preventing complications is a key part of managing leukopenia. Individuals with low white blood cell counts are often advised to follow strict hygiene practices, avoid exposure to sick individuals, and seek medical attention promptly if they develop signs of infection. In some cases, dietary precautions or environmental adjustments may be recommended depending on severity.

Leukopenia is also closely monitored in patients undergoing treatments such as chemotherapy. Regular blood tests are used to track white blood cell levels, and treatment schedules may be adjusted to allow recovery of the immune system. This careful balance helps ensure that cancer treatment remains effective while minimizing the risk of infection.

CONCLUSION

In conclusion, leukopenia is a medical condition characterized by a reduced number of white blood cells, leading to increased vulnerability to infections. It can result from a wide range of causes, including bone marrow disorders, medications, infections, autoimmune diseases such as Systemic Lupus Erythematosus, and nutritional deficiencies. While it may not always produce direct symptoms, its impact on immune function can be significant. Early diagnosis, identification of the underlying cause, and appropriate management are essential for preventing complications and restoring healthy immune function.

REFERENCES

1. Rohr LR, Rivers FM. Spurious automated leukopenia due to in vitro granulocyte aggregation. Am J Clin Pathol 1990;93:572-574.
2. Epstein HD, Kruskall MS. Spurious leukopenia due to in vitro granulocyte aggregation. Am J Clin Pathol 1988;89:652-655.
3. Berliner S, Fusman R, Rotstein R, Avitzour D, Shapira I, Zeltser D. Electronic counter-related pseudoleukopenia: More than a rare occurrence. Haematologica 2001;86:210-211.
4. Berliner S, Fishelson Z, Bruhis S, Kaufman H, Pinhas J, Aronson M. The phenomenon of leukergy: induction and detection of leukocyte aggregation in whole human blood. J Lab Clin Med 1987;109:575-582.
5. Maharshak N, Kassirer M, Zeltser D, Rotstein R, Rogowski O, Shapira I, et al. The inflammation meter: novel technology to detect the presence of infection/inflammation in patients without leukocytosis but with an increased leukocyte adhesiveness/aggregation. Acta Haematol 2000;104:16-21.
6. Fusman R, Zeltser D, Rotstein R, Chapman J, Avitzour D, Shapira I, Eldor A, et al. INFLAMET: An image analyzer to display erythrocyte adhesiveness/aggregation. Eur J Int Med 2000;11:271-276.
7. Rogowski O, Zeltser D, Rotstein R, Shapira I, Avitzour D, Fusman R,et al. Correlated expression of adhesive properties for both white and red blood cells during inflammation. Biorheology 2000;37:361-370.
8. Berliner AS, Shapira I, Rogowski O, Sadees N, Rotstein R, Fusman R, et al. Combined leukocyte and erythrocyte aggregation in the peripheral venous blood during sepsis. A clue to the presence of a commonly shared adhesive protein(s). Int J Clin Lab Res 2000;30:27-31.
9. Rotstein R, Zeltser D, Shapira I, Berliner S, Avitzour D, Dwolatzky T, et al. An inflammation meter to reveal the presence and extent of inflammation in older patients. J Am Geriat Soc 2000;48:1739-1741.
10. Fusman R, Zeltser D, Rotstein R, Chapman J, Avitzour D, Shapira I, et al. The picture of inflammation: A new concept that combines the white blood cell count and erythrocyte sedimentation rate into a new hematologic diagnostic modality. Acta Haematol 2001;106:106-114.